<DOC>
	<DOC>NCT00656630</DOC>
	<brief_summary>The purpose of this study is to develop and validate a human laboratory model for prediction of medication efficacy in clinical trials for relapse prevention in alcohol dependence.</brief_summary>
	<brief_title>Medication Development in Alcoholism: Acamprosate Versus Naltrexone</brief_title>
	<detailed_description>This is a double-blind, 3-cell, outpatient human laboratory study to determine the degree to which acamprosate and naltrexone will suppress subjective and physiological responsivity to alcohol cues relative to placebo in early abstinence.</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Males or females ≥ 18 and ≤ 55 years of age Meets Diagnostic and Statistical ManualFourth Edition (DSMIV) criteria for current alcohol dependence Does not desire treatment Alcohol free, as verified by breath alcohol concentration, with a Clinical Institute Withdrawal Assessment (CIWA) ≤ 8, at the time of testing, with no evidence of drinking for at least 3 days but no more than 7 days prior to the cue reactivity session Able to complete and understand questionnaires and study procedures in English Verbal I.Q. estimate ≥ 85 Signed informed consent Currently meets DSMIV criteria for dependence on substances other than alcohol or nicotine Significant medical disorders that will increase potential risk or interfere with study participation Sexually active women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control Meets DSMIV criteria for a major Axis I disorder, including depression or anxiety disorders Treatment within the month prior to screening with investigational medications or those which may influence drinking outcome, e.g., disulfiram (Antabuse), naltrexone (ReVia), acamprosate (Campral), antidepressants or other psychotropic agents Chronic treatment with any narcoticcontaining medications during the previous month or evidence of current opiate use Liver function tests more than three times normal or elevated bilirubin No fixed domicile and/or no availability by telephone or beeper Current involvement in or plans for treatment prior to study completion Patients who have a history of adverse drug reactions to the study drugs or their ingredients Failure to take doubleblind medication as prescribed Inability to understand or comply with the provisions of the protocol or consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>